2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Carbon Flux as a Measure of Prostate Cancer Aggressiveness: [ 11C]-Acetate PET/CT

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose: Dynamic [ 11C]-acetate positron emission tomography (PET) can be used to study tissue perfusion and carbon flux simultaneously. In this study, the feasibility of the quantification of prostate cancer aggressiveness using parametric methods assessing [ 11C]-acetate kinetics was investigated in prostate cancer subjects. The underlying uptake mechanism correlated with [ 11C]-acetate influx and efflux measured in real-time in vitro in cell culture.

          Methods: Twenty-one patients with newly diagnosed low-to-moderate risk prostate cancer underwent magnetic resonance imaging (MRI) and dynamic [ 11C]-acetate PET/CT examinations of the pelvis. Parametric images of K 1 (extraction × perfusion), k 2 (oxidative metabolism) and V T (=K 1/k 2, anabolic metabolism defined as carbon retention) were constructed using a one-tissue compartment model with an arterial input function derived from pelvic arteries. Regions of interest (ROIs) of the largest cancer lesion in each patient and normal prostate tissue were drawn using information from MRI (T2 and DWI images), biopsy results, and post-surgical histopathology of whole prostate sections (n=7). In vitro kinetics of [ 11C]-acetate were studied on DU145 and PC3 cell lines using LigandTracer ® White equipment for the measurement of the radioactivity uptake in real-time at 37°C.

          Results: Mean prostate specific antigen (PSA) was 8.33±3.92 ng/mL and median Gleason Sum 6 (range 5-7). K 1, V T and standardized uptake values (SUVs) were significantly higher in cancerous prostate tissues compared to normal ones for all patients (p<0.001), while k 2 was not (p=0.26). PSA values correlated to early SUVs (r=0.50, p=0.02) and K 1 (r=0.48, p=0.03). Early and late SUVs correlated to V T (r>0.76, p<0.001) and K 1 (r>0.64, p<0.005). In vitro studies demonstrated higher extraction and retention (p<0.01) of [ 11C]-acetate in the more aggressive PC3 cells.

          Conclusion: Parametric images could be used to visualize the [ 11C]-acetate kinetics of the prostate cancer exhibiting elevated extraction associated with the cancer aggressiveness. The influx rate of [ 11C]-acetate studied in cell culture also showed dependence on the cancer aggressiveness associated with elevated lipogenesis. Dynamic [ 11C]-acetate/PET demonstrated potential for prostate cancer aggressiveness estimation using parametric-based K 1 and V T values.

          Related collections

          Most cited references37

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.

          PURPOSE We assessed the outcome of a watchful-waiting protocol with selective delayed intervention by using clinical prostate-specific antigen (PSA), or histologic progression as treatment indications for clinically localized prostate cancer. PATIENTS AND METHODS This was a prospective, single-arm, cohort study. Patients were managed with an initial expectant approach. Definitive intervention was offered to those patients with a PSA doubling time of less than 3 years, Gleason score progression (to 4 + 3 or greater), or unequivocal clinical progression. Survival analysis and Cox proportional hazard model were applied to the data. Results A total of 450 patients have been observed with active surveillance. Median follow-up was 6.8 years (range, 1 to 13 years). Overall survival was 78.6%. The 10-year prostate cancer actuarial survival was 97.2%. Overall, 30% of patients have been reclassified as higher risk and have been offered definitive therapy. Of 117 patients treated radically, the PSA failure rate was 50%, which was 13% of the total cohort. PSA doubling time of 3 years or less was associated with an 8.5-times higher risk of biochemical failure after definitive treatment compared with a doubling time of more than 3 years (P < .0001). The hazard ratio for nonprostate cancer to prostate cancer mortality was 18.6 at 10 years. CONCLUSION We observed a low rate of prostate cancer mortality. Among the patients who were reclassified as higher risk and who were treated, PSA failure was relatively common. Other-cause mortality accounted for almost all of the deaths. Additional studies are warranted to improve the identification of patients who harbor more aggressive disease despite favorable clinical parameters at diagnosis.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Metabolic alterations and targeted therapies in prostate cancer.

            Cancer cells synthesize de novo large amounts of fatty acids and cholesterol, irrespective of the circulating lipid levels and benefit from this increased lipid synthesis in terms of growth advantage, self-survival and drug resistance. Key lipogenic alterations that commonly occur in prostate cancer include over-expression of the enzyme fatty acid synthase (FASN) and deregulation of the 5-AMP-activated protein kinase (AMPK). FASN is a key metabolic enzyme that catalyses the synthesis of palmitate from the condensation of malonyl-CoA and acetyl-CoA de novo and plays a central role in energy homeostasis, by converting excess carbon intake into fatty acids for storage. AMPK functions as a central metabolic switch that governs glucose and lipid metabolism. Recent interest has focused on the potential of targeting metabolic pathways that may be altered during prostate tumorigenesis and progression. Several small molecule inhibitors of FASN have now been described or in development for therapeutic use; in addition, drugs that directly or indirectly induce AMPK activation have potential benefit in prostate cancer prevention and treatment. Copyright © 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Multiparametric MRI of prostate cancer: an update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer.

              Magnetic resonance (MR) examinations of men with prostate cancer are most commonly performed for detecting, characterizing, and staging the extent of disease to best determine diagnostic or treatment strategies, which range from biopsy guidance to active surveillance to radical prostatectomy. Given both the exam's importance to individual treatment plans and the time constraints present for its operation at most institutions, it is essential to perform the study effectively and efficiently. This article reviews the most commonly employed modern techniques for prostate cancer MR examinations, exploring the relevant signal characteristics from the different methods discussed and relating them to intrinsic prostate tissue properties. Also, a review of recent articles using these methods to enhance clinical interpretation and assess clinical performance is provided. J. Magn. Reson. Imaging 2013;37:1035-1054. © 2013 Wiley Periodicals, Inc.
                Bookmark

                Author and article information

                Journal
                Int J Med Sci
                Int J Med Sci
                ijms
                International Journal of Medical Sciences
                Ivyspring International Publisher (Sydney )
                1449-1907
                2020
                14 January 2020
                : 17
                : 2
                : 214-223
                Affiliations
                [1 ]Division of Nuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
                [2 ]Division of Urology, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
                [3 ]Division of Molecular Imaging, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
                [4 ]Medical Physics, Uppsala University Hospital, Uppsala, Sweden
                [5 ]Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
                [6 ]PET Centre, Uppsala University Hospital, Uppsala, Sweden
                Author notes
                ✉ Corresponding author: Naresh Regula, MBBS, PhD student at Uppsala University, Sweden, Tel: +46765647494; E-mail: naresh.regula@ 123456surgsci.uu.se

                *These authors contributed equally to this work

                Competing Interests: The authors have declared that no competing interest exists.

                Article
                ijmsv17p0214
                10.7150/ijms.39542
                6990881
                1555afc7-be24-43fc-ad9c-041f2d03f338
                © The author(s)

                This is an open access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

                History
                : 22 October 2019
                : 12 December 2019
                Categories
                Research Paper

                Medicine
                carbon-11 acetate,positron emission tomography,prostate cancer,dynamic imaging
                Medicine
                carbon-11 acetate, positron emission tomography, prostate cancer, dynamic imaging

                Comments

                Comment on this article